Physician profile
Michael Skolnick
NPI 1144843616
$1,632.70
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $92.55 · 2023: $1,098 · 2024: $442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,459 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,459.16 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $302.60 | 2023-2024 | Spravato, Invega Sustenna |
| Abbvie INC. | $201.24 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $182.07 | 2022-2024 | Austedo Xr, Austedo, Uzedy |
| Neurocrine Biosciences, INC. | $166.65 | 2023-2024 | Ingrezza |
| Alkermes, INC. | $150.41 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.17 | 2023-2024 | Caplyta |
| Lundbeck LLC | $95.16 | 2023-2024 | Rexulti |
| Corium, LLC | $93.44 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $82.57 | 2022-2023 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $56.92 | 2023-2024 | Trintellix |
| Acadia Pharmaceuticals INC | $41.29 | 2022-2023 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $33.74 | 2023 | Qelbree |
| Novo Nordisk INC | $27.58 | 2024 | |
| Axsome Therapeutics, INC. | $23.26 | 2024 | Auvelity |
| Vertical Pharmaceuticals, LLC | $20.62 | 2024 | Relexxii |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $20.49 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.49 | 2023 | Abilify Maintena, Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Skolnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.